Table 1 Clinicopathological characteristics of 80 invasive breast cancer patients
Characteristic | Long- term survivors ≥8 years | Short-term survivors <8 years |
|---|---|---|
No. of patients (%) | ||
Mean age (years) | 55 (27–73) | 51 (33–72) |
Histologic type | ||
Invasive ductal | 33 (82.5) | 31 (77.5) |
Invasive lobular | 3 (7.5) | 7 (17.5) |
Invasive ductal + lobular | 0 (0) | 1 (2.5) |
Other | 3 (7.5) | 1 (2.5) |
Not available | 1 (2.5) | 0 (0) |
Pathologic tumor size (mm) | ||
pT1 (0–20) | 8 (20) | 8 (20) |
pT2 (>20-50) | 27 (67.5) | 29 (72.5) |
pT3 (>50) | 5 (12.5) | 3 (7.5) |
BRE grade | ||
I-II | 21 (100) | 20 (100) |
III | 19 (100) | 20 (100) |
No. of axillary lymph nodes | ||
0 | 14 (35) | 14 (35) |
1-3 | 12 (30) | 12 (30) |
≥4 | 14 (35) | 14 (35) |
ER/PR receptor | ||
Negative | 19 (47.5) | 20 (50) |
Positive | 20 (50) | 20 (50) |
Not available | 1 (2.5) | 0 (0) |
HER2 status | ||
Positive | 15 (37.5) | 11 (27.5) |
Negative | 21 (52.5) | 20 (50) |
Not available | 4 (10) | 9 (22.5) |
Surgery | ||
Lumpectomy | 15 (37.5) | 15 (37.5) |
Mastectomy | 25 (62.5) | 25 (62.5) |
Radiotherapy | ||
No | 19 (86) | 19 (47.5) |
Yes | 11 (20) | 20 (50) |
Not available | 2 (9) | 1 (2.5) |
Chemotherapy | ||
No | 12 (36.5) | 16 (41) |
Yes | 17 (51.5) | 23 (59) |
Not available | 4 (12) | 0 (0) |
Endocrine therapy | ||
No | 15 (45.5) | 20 (51) |
Yes | 13 (39.5) | 18 (46) |
Not available | 5 (15) | 1 (3) |
Recurrence | ||
No | 15 (45) | 10 (25) |
Yes | 3 (10) | 15 (37.5) |
Not available | 15 (45) | 15 (37.5) |